369 related articles for article (PubMed ID: 17285366)
1. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
[TBL] [Abstract][Full Text] [Related]
2. Dopamine agonist-resistant prolactinomas.
Oh MC; Aghi MK
J Neurosurg; 2011 May; 114(5):1369-79. PubMed ID: 21214334
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide in the management of dopamine agonist-resistant prolactinomas.
Whitelaw BC; Dworakowska D; Thomas NW; Barazi S; Riordan-Eva P; King AP; Hampton T; Landau DB; Lipscomb D; Buchanan CR; Gilbert JA; Aylwin SJ
Clin Endocrinol (Oxf); 2012 Jun; 76(6):877-86. PubMed ID: 22372583
[TBL] [Abstract][Full Text] [Related]
4. A case of a prolactinoma resistant to dopamine agonists.
Vourliotaki I; Bonapart IE; Stamataki C; Tsapakis EM; Saridaki C
Hormones (Athens); 2005; 4(3):165-70. PubMed ID: 16613827
[TBL] [Abstract][Full Text] [Related]
5. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide.
Felker J; Patterson B; Wrubel D; Janss A
J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1413-1415. PubMed ID: 27815961
[TBL] [Abstract][Full Text] [Related]
7. Early Recognition and Initiation of Temozolomide Chemotherapy for Refractory, Invasive Pituitary Macroprolactinoma with Long-Term Sustained Remission.
Barkhoudarian G; Palejwala SK; Ogunbameru R; Wei H; Eisenberg A; Kelly DF
World Neurosurg; 2018 Oct; 118():118-124. PubMed ID: 30031177
[TBL] [Abstract][Full Text] [Related]
8. Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
Almalki MH; Aljoaib NN; Alotaibi MJ; Aldabas BS; Wahedi TS; Ahmad MM; Alshahrani F
Hormones (Athens); 2017 Apr; 16(2):139-149. PubMed ID: 28742502
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists.
Tang H; Cheng Y; Huang J; Li J; Zhang B; Wu ZB
Front Endocrinol (Lausanne); 2021; 12():616339. PubMed ID: 33776913
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings.
Kovacs K; Horvath E; Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE
Hum Pathol; 2007 Jan; 38(1):185-9. PubMed ID: 17056093
[TBL] [Abstract][Full Text] [Related]
11. Visual vignette. Prolactinoma.
Mayrin JV; Donahue JE; Laufgraben MJ
Endocr Pract; 2008 Mar; 14(2):256. PubMed ID: 18308671
[No Abstract] [Full Text] [Related]
12. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
Chen C; Yin S; Zhang S; Wang M; Hu Y; Zhou P; Jiang S
Medicine (Baltimore); 2017 Nov; 96(47):e8733. PubMed ID: 29381964
[TBL] [Abstract][Full Text] [Related]
13. Resistant prolactinomas.
Vasilev V; Daly AF; Vroonen L; Zacharieva S; Beckers A
J Endocrinol Invest; 2011 Apr; 34(4):312-6. PubMed ID: 21406957
[TBL] [Abstract][Full Text] [Related]
14. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
15. Aggressive prolactinomas: how to manage?
Lasolle H; Ilie MD; Raverot G
Pituitary; 2020 Feb; 23(1):70-77. PubMed ID: 31617128
[TBL] [Abstract][Full Text] [Related]
16. Prolactin, prolactin disorders, and dopamine agonists during pregnancy.
Levin G; Rottenstreich A
Hormones (Athens); 2019 Jun; 18(2):137-139. PubMed ID: 30341577
[TBL] [Abstract][Full Text] [Related]
17. Management of Dopamine Agonist-Resistant Prolactinoma.
Maiter D
Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
[TBL] [Abstract][Full Text] [Related]
18. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy.
Cackett P; Eunson G; Bath L; Mulvihill A
Future Oncol; 2012 Dec; 8(12):1621-6. PubMed ID: 23231524
[TBL] [Abstract][Full Text] [Related]
19. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
20. Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
de Castro LF; Magalhães Gonzaga MF; Naves LA; Luiz Mendonça J; Oton de Lima B; Casulari LA
Horm Res Paediatr; 2018; 89(1):63-70. PubMed ID: 28954263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
